Isommune: Pioneering in tumor-specific molecule detection for early cancer diagnosis and therapy development.
Identifying molecules that are specific to tumors for use in early detection, diagnosis, prognosis, and therapy is both a primary goal and a key discovery challenge across diverse areas of oncology. To discover tumor-specific molecules, Isommune has developed custom bioinformatics algorithms to analyze transcriptome sequencing data to identify candidate tumor-specific mRNA isoforms and a separate computational and wet lab infrastructure for high-throughput RT–qPCR validation of candidate isoforms.
Our process reveals multiple candidate diagnostic and therapeutic targets with unique sequences that are expressed in many tumor instances but not in normal tissues. Isommune is in the process of applying its discovery process to much of the transcriptome sequencing data that now exists worldwide. The results of our analyses will be the identity of mRNA isoforms that will form the basis of multiple therapeutic development efforts. The therapeutic efforts will be based on tumor-specific mRNA isoforms that encode tumor-specific protein isoforms that are suitable targets for monoclonal antibodies or that can be used in anti-cancer peptide vaccines.
Isommune's most recent funding round was for $275k (USD) in May 2016.
As of May 4, 2016, Isommune has disclosed funding of $275k (USD).

Isabl
isabl.io

Personalis
personalis.com

Kernal Biologics
kernalbio.com

Immunitas Therapeutics
immunitastx.com

Imvaq Therapeutics

Cofactor Genomics

INmune Bio
inmunebio.com

ImmunoGenesis
immunogenesis.com

Immunome
immunome.com

Micronoma
micronoma.com

Gamgee
gamgee.io

Immuneering
immuneering.com

Immunicom
immunicom.com

Immunai
immunai.com

Syncromune
syncromune.com

Iovance Biotherapeutics
iovance.com

Immune-Onc Therapeutics
immuneonc.com
Liquid Genomics

RNAimmune
rnaimmune.com

Epinoma
epinoma.com